The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1389
ISSUE1389
April 30, 2012
Indacaterol (Arcapta Neohaler) for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Indacaterol (Arcapta Neohaler) for COPD
April 30, 2012 (Issue: 1389)
The FDA has approved indacaterol (in´´ da ka´ ter ol; Arcapta Neohaler – Novartis), an inhaled long-acting beta2-agonist, for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.